Cupping in Fibromyalgia (CuFib)

May 4, 2018 updated by: Jost Langhorst, Universität Duisburg-Essen

Randomized Controlled Pilot Trial: The Effectiveness of Cupping in Patients With Fibromyalgia

The purpose of this randomized controlled study is to determine the effectiveness of cupping in patients with fibromyalgia compared to sham cupping.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

see above

Study Type

Interventional

Enrollment (Actual)

141

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Essen, Germany, 45276
        • Klinik für Naturheilkunde

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • FMS diagnosis according to AWMF Guidelines,
  • necessary documents: medical records
  • Pain intensity > 45mm VAS
  • Participation in cupping twice weekly on appointment

Exclusion Criteria:

  • pregnancy
  • other study participation
  • pain due to other rheumatic disease
  • major psychiatric disorder
  • substance abuse
  • severe somatic disorder (cancer)
  • injections, acupuncture, neural therapy within the past 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham Cupping
Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
Experimental: Cupping Therapy
Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
No Intervention: Wait list
Wait list control no specific intervention for 3 weeks study period

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Intensity
Time Frame: Day 18
Pain on a 100mm visual analog scale
Day 18

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Intensity
Time Frame: Day 200
Pain intensity measured on a 100mm visual analog scale
Day 200
Fatigue
Time Frame: Day 18
Fatigue measured by the Multidimensional Fatigue Inventory (MFI) (Smets, Garssen, Bonke et al., 1995
Day 18
Fatigue
Time Frame: Day 200
Fatigue measured by the Multidimensional Fatigue Inventory (MFI) (Smets, Garssen, Bonke et al., 1995
Day 200
Sleep Quality
Time Frame: Day 18
measured by the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al. 1989)
Day 18
Sleep Quality
Time Frame: Day 200
measured by the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al. 1989)
Day 200
Quality of life
Time Frame: Day 18
measured by the SF-36 (Bullinger & Kirchberger, 1998)
Day 18
Quality of life
Time Frame: Day 200
measured by the SF-36 (Bullinger & Kirchberger, 1998)
Day 200
Medication
Time Frame: Day 18
measured by a medication log, daily entering of used drugs
Day 18
adverse events
Time Frame: Day 18
all adverse events
Day 18
Pressure pain sensitivity
Time Frame: Day 18
using an electronic algometer (Somedic, Sweden) to determine threshold of pain perception on predefined muscles
Day 18
Disability
Time Frame: Day 18
measured by the FI (fibromyalgia impact questionnaire) (Offenbaecher, Waltz, Schoeps , 2000)
Day 18
Disability
Time Frame: Day 200
measured by the FI (fibromyalgia impact questionnaire) (Offenbaecher, Waltz, Schoeps , 2000)
Day 200

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jost Langhorst, MD, Prof, University of Duisburg-Essen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

March 1, 2015

Study Registration Dates

First Submitted

July 3, 2012

First Submitted That Met QC Criteria

July 6, 2012

First Posted (Estimate)

July 9, 2012

Study Record Updates

Last Update Posted (Actual)

May 11, 2018

Last Update Submitted That Met QC Criteria

May 4, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fibromyalgia

Clinical Trials on Cupping therapy

Subscribe